{"success":true,"data":{"pressRelease":{"id":"172683","rtpr_id":"nGNXc0rll-20261019","ticker":"RXST","exchange":"NASDAQ","all_tickers":["RXST"],"title":"RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation","author":"Globe Newswire","published_at":"2026-10-19T13:00:00.133Z","article_body":"ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:\nRXST) today announced the appointments of Taryn Conway as Chief Commercial\nOfficer and Frank Shields as Executive Vice President of Sales and Commercial\nStrategy. The appointments strengthen RxSight’s commercial leadership team\nand support the company’s efforts to enhance commercial execution and\naccelerate adoption of RxSight’s Light Adjustable Lens™ (LAL™)\ntechnology.\n\n“Over the past several months, we have prioritized investment to strengthen\nour commercial organization, and the appointments of Taryn and Frank are\nanother important step in that process,” said Aziz Mottiwala, President and\nChief Executive Officer of RxSight. “Their extensive experience in eye care\nand track record of driving the adoption of innovative technologies will be\ninstrumental as we advance the next phase of our commercial strategy, with a\ngreater emphasis on customer engagement and utilization.”\n\nTaryn Conway, Chief Commercial Officer\n\nConway brings more than 20 years of experience building commercial\norganizations across eye care, pharmaceuticals and medical aesthetics. Most\nrecently, she served as Vice President of Medical and Scientific Affairs at\nBausch + Lomb, overseeing medical strategy across its pharmaceutical and\nconsumer businesses. Prior to that, she was General Manager of Aesthetics at\nRevance Therapeutics, where she built and scaled a commercial organization\nfrom the ground up and led the commercialization of two major product lines.\nEarlier in her career, she held senior leadership positions at Allergan,\ndeveloping deep expertise in ophthalmology, physician engagement and market\ndevelopment.\n\nFrank Shields, Executive Vice President of Sales and Commercial Strategy\n\nShields brings over 30 years of ophthalmology leadership experience, with a\ndistinguished record of guiding commercial organizations, launching\ntransformative technologies, and building lasting relationships with\nphysicians, customers, and industry partners. Prior to joining RxSight, he\nserved as a Head of U.S. Surgical Glaucoma at Bausch + Lomb following its\nacquisition of Elios Vision, where he was President. Earlier, he held sales\nleadership roles at Ivantis, Revision Optics and Bausch + Lomb, with\nexperience across cataract, refractive and glaucoma technologies.\n\nThese appointments are part of RxSight's broader commercial transformation,\nwhich includes expanding and realigning its field organization to enable\ndeeper customer engagement and increased support, so even more patients can\nbenefit from RxSight’s LAL technology. The changes are designed to help\npractices integrate this differentiated technology into their workflows and\naddress barriers to broader utilization.\n\nAbout RxSight, Inc.\n\nRxSight, Inc. is an ophthalmic medical device company dedicated to providing\nhigh-quality customized vision to patients following cataract surgery. The\nLight Adjustable Lens™ system, comprised of the RxSight Light Adjustable\nLens™ products (LAL™ and LAL+™), RxSight Light Delivery Device™\n(LDD™), and accessories, is the first and only commercially available\nintraocular lens (IOL) technology that can be adjusted after surgery, enabling\ndoctors to customize and deliver high-quality vision to patients after\ncataract surgery. Additional information about RxSight can be found at\nwww.rxsight.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act and Section 21E of the Exchange Act. All\nstatements in this press release that are not purely historical are\nforward-looking statements, including, without limitation, statements\nregarding the RxSight’s business initiatives and prospects.\n\nSuch statements relate to future events or our future financial performance\nand involve known and unknown risks, uncertainties and other factors that may\ncause our or our industry's actual results, levels of activity, performance or\nachievements to be materially different from any future results, levels of\nactivity, performance or achievements expressed, implied or inferred by these\nforward-looking statements, including those risks described in the RxSight’s\nprior press releases and the company’s filings with the Securities and\nExchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of the\ncompany’s Quarterly Report on Form 10-Q for the period ended June 30, 2026,\nfiled with the SEC on August 5, 2026, and any subsequent filings with the SEC.\nThese statements are only predictions based on our current expectations and\nprojections about future events. Actual events or results may differ\nmaterially. RxSight undertakes no obligation to update any of the\nforward-looking statements after the date of this press release to conform\nthose statements to reflect the occurrence of unanticipated events, except as\nrequired by applicable law.\n\nLight Adjustable Lens™, LAL™, LAL+™, Light Delivery Device™ and LDD™\nare trademarks of RxSight, Inc.\n\nInvestor Relations Contact:\nOliver Moravcevic\nVP, Investor Relations\nomoravcevic@rxsight.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/48441335-c938-45ff-9355-ba8e331354e9)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXc0rll-20261019","title":"RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation","author":"Globe Newswire","ticker":"RXST","created":"2026-10-19T13:00:00.133Z","tickers":["RXST"],"exchange":"NASDAQ","article_body":"ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:\nRXST) today announced the appointments of Taryn Conway as Chief Commercial\nOfficer and Frank Shields as Executive Vice President of Sales and Commercial\nStrategy. The appointments strengthen RxSight’s commercial leadership team\nand support the company’s efforts to enhance commercial execution and\naccelerate adoption of RxSight’s Light Adjustable Lens™ (LAL™)\ntechnology.\n\n“Over the past several months, we have prioritized investment to strengthen\nour commercial organization, and the appointments of Taryn and Frank are\nanother important step in that process,” said Aziz Mottiwala, President and\nChief Executive Officer of RxSight. “Their extensive experience in eye care\nand track record of driving the adoption of innovative technologies will be\ninstrumental as we advance the next phase of our commercial strategy, with a\ngreater emphasis on customer engagement and utilization.”\n\nTaryn Conway, Chief Commercial Officer\n\nConway brings more than 20 years of experience building commercial\norganizations across eye care, pharmaceuticals and medical aesthetics. Most\nrecently, she served as Vice President of Medical and Scientific Affairs at\nBausch + Lomb, overseeing medical strategy across its pharmaceutical and\nconsumer businesses. Prior to that, she was General Manager of Aesthetics at\nRevance Therapeutics, where she built and scaled a commercial organization\nfrom the ground up and led the commercialization of two major product lines.\nEarlier in her career, she held senior leadership positions at Allergan,\ndeveloping deep expertise in ophthalmology, physician engagement and market\ndevelopment.\n\nFrank Shields, Executive Vice President of Sales and Commercial Strategy\n\nShields brings over 30 years of ophthalmology leadership experience, with a\ndistinguished record of guiding commercial organizations, launching\ntransformative technologies, and building lasting relationships with\nphysicians, customers, and industry partners. Prior to joining RxSight, he\nserved as a Head of U.S. Surgical Glaucoma at Bausch + Lomb following its\nacquisition of Elios Vision, where he was President. Earlier, he held sales\nleadership roles at Ivantis, Revision Optics and Bausch + Lomb, with\nexperience across cataract, refractive and glaucoma technologies.\n\nThese appointments are part of RxSight's broader commercial transformation,\nwhich includes expanding and realigning its field organization to enable\ndeeper customer engagement and increased support, so even more patients can\nbenefit from RxSight’s LAL technology. The changes are designed to help\npractices integrate this differentiated technology into their workflows and\naddress barriers to broader utilization.\n\nAbout RxSight, Inc.\n\nRxSight, Inc. is an ophthalmic medical device company dedicated to providing\nhigh-quality customized vision to patients following cataract surgery. The\nLight Adjustable Lens™ system, comprised of the RxSight Light Adjustable\nLens™ products (LAL™ and LAL+™), RxSight Light Delivery Device™\n(LDD™), and accessories, is the first and only commercially available\nintraocular lens (IOL) technology that can be adjusted after surgery, enabling\ndoctors to customize and deliver high-quality vision to patients after\ncataract surgery. Additional information about RxSight can be found at\nwww.rxsight.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act and Section 21E of the Exchange Act. All\nstatements in this press release that are not purely historical are\nforward-looking statements, including, without limitation, statements\nregarding the RxSight’s business initiatives and prospects.\n\nSuch statements relate to future events or our future financial performance\nand involve known and unknown risks, uncertainties and other factors that may\ncause our or our industry's actual results, levels of activity, performance or\nachievements to be materially different from any future results, levels of\nactivity, performance or achievements expressed, implied or inferred by these\nforward-looking statements, including those risks described in the RxSight’s\nprior press releases and the company’s filings with the Securities and\nExchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of the\ncompany’s Quarterly Report on Form 10-Q for the period ended June 30, 2026,\nfiled with the SEC on August 5, 2026, and any subsequent filings with the SEC.\nThese statements are only predictions based on our current expectations and\nprojections about future events. Actual events or results may differ\nmaterially. RxSight undertakes no obligation to update any of the\nforward-looking statements after the date of this press release to conform\nthose statements to reflect the occurrence of unanticipated events, except as\nrequired by applicable law.\n\nLight Adjustable Lens™, LAL™, LAL+™, Light Delivery Device™ and LDD™\nare trademarks of RxSight, Inc.\n\nInvestor Relations Contact:\nOliver Moravcevic\nVP, Investor Relations\nomoravcevic@rxsight.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/48441335-c938-45ff-9355-ba8e331354e9)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-19T13:00:00.217731649Z","server_sent_at_ms":1792414800217},"received_at":"2026-10-19T13:00:00.274Z","source_url":null},"analysis":{"id":"160802","press_release_id":"172683","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"RxSight appointed Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy, strengthening its commercial leadership team.\n\nBoth hires bring deep ophthalmology and eye-care commercial experience, most recently at Bausch + Lomb, with Conway previously at Revance and Allergan and Shields at Elios Vision and Ivantis.\n\nThe appointments are part of a broader commercial transformation aimed at deepening customer engagement and accelerating adoption and utilization of the Light Adjustable Lens system.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"RxSight doubles down on commercial execution with veteran eye-care hires to lift LAL utilization."},"keyFigures":{},"quotedText":"Their extensive experience in eye care and track record of driving the adoption of innovative technologies will be instrumental as we advance the next phase of our commercial strategy, with a greater emphasis on customer engagement and utilization.","namedEntities":{"people":[{"name":"Taryn Conway","role":"Chief Commercial Officer (new appointee)"},{"name":"Frank Shields","role":"EVP of Sales and Commercial Strategy (new appointee)"},{"name":"Aziz Mottiwala","role":"President and CEO"},{"name":"Oliver Moravcevic","role":"VP, Investor Relations"}],"products":["Light Adjustable Lens (LAL)","LAL+","Light Delivery Device (LDD)"],"companies":[{"name":"RxSight, Inc.","ticker":"RXST"},{"name":"Bausch + Lomb","relationship":"prior employer of both appointees"},{"name":"Revance Therapeutics","relationship":"prior employer of Taryn Conway"},{"name":"Allergan","relationship":"prior employer of Taryn Conway"},{"name":"Elios Vision","relationship":"prior employer of Frank Shields"},{"name":"Ivantis","relationship":"prior employer of Frank Shields"},{"name":"Revision Optics","relationship":"prior employer of Frank Shields"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Appointment of a Chief Commercial Officer and an EVP of Sales as part of a commercial transformation — meaningful but routine leadership additions, not a CEO/CFO departure or change."},"tickerRelevance":{"others":[],"primary":"RXST"},"globalImportance":22,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-to-mid-cap medical device","eventGravity":"executive appointments (non-CEO/CFO)","issuerAuthored":true,"householdBrandBoost":false}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"RxSight appointed Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy, strengthening its commercial leadership team.\n\nBoth hires bring deep ophthalmology and eye-care commercial experience, most recently at Bausch + Lomb, with Conway previously at Revance and Allergan and Shields at Elios Vision and Ivantis.\n\nThe appointments are part of a broader commercial transformation aimed at deepening customer engagement and accelerating adoption and utilization of the Light Adjustable Lens system.","key_figures":{},"named_entities":{"people":[{"name":"Taryn Conway","role":"Chief Commercial Officer (new appointee)"},{"name":"Frank Shields","role":"EVP of Sales and Commercial Strategy (new appointee)"},{"name":"Aziz Mottiwala","role":"President and CEO"},{"name":"Oliver Moravcevic","role":"VP, Investor Relations"}],"products":["Light Adjustable Lens (LAL)","LAL+","Light Delivery Device (LDD)"],"companies":[{"name":"RxSight, Inc.","ticker":"RXST"},{"name":"Bausch + Lomb","relationship":"prior employer of both appointees"},{"name":"Revance Therapeutics","relationship":"prior employer of Taryn Conway"},{"name":"Allergan","relationship":"prior employer of Taryn Conway"},{"name":"Elios Vision","relationship":"prior employer of Frank Shields"},{"name":"Ivantis","relationship":"prior employer of Frank Shields"},{"name":"Revision Optics","relationship":"prior employer of Frank Shields"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-19T13:00:05.273Z","global_importance":22,"audience_relevance":25,"importance_components":{"tickerTier":"small-to-mid-cap medical device","eventGravity":"executive appointments (non-CEO/CFO)","issuerAuthored":true,"householdBrandBoost":false}},"durationMs":null,"modelName":"glm-5.3-flashx"}}